ChemFeeds Site Navigation:
Journal Selection:
Search:

1) Vintafolide Resistance (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


2) Afatinib for ESCC or HNSCC (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


3) Targeting ERK1 in DC Vaccines for Glioma (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


4) AKT3 and Breast Tumor Resistance (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


5) The MAPK Pathway Facilitates Resistance to Dasatinib (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


6) AR in CD4+ T Cells Conducted Bladder Cancer Tumor Microenvironment (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


7) Emodin Blocks Cancer Cell-Macrophage Interaction (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


8) HPV-Induced Tumors Controlled by CD8+ Cells and MDSC Depletion (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


9) Overcoming SN-38-ADC Drug Resistance (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


10) SYD985 in Uterine Serous Carcinoma with HER2/Neu Expression (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


11) A New Anti-CXCR4 Antibody (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


12) Macrophage-Mediated Trogocytosis Can Kill Cancer Cells (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


13) ADCs with Potent DNA Alkylating Agents (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


14) Vemurafenib and PAC-1 Are Synergistic in Mutant BRAF Melanomas (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


15) Reversal of MDR by Osimertinib (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


16) Targeted PDT Treatment of Prostate Cancer (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


17) BET Inhibitors for Triple-Negative Breast Cancer (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


18) MLN8237 plus Eribulin Eradicates Metastases via Autophagy (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


19) Radiosensitization of Medulloblastoma by Inhibition of MRK (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


20) MYC and Pancreatic Cancer (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


21) ATM Mutations in Cancer (Molecular Cancer Therapeutics) Wednesday August 3rd 2016


22) Chromatin Regulators for Chemotherapy Response (Molecular Cancer Therapeutics) Wednesday July 6th 2016


23) NQO1-Dependent Radiosensitization of Head and Neck Cancer (Molecular Cancer Therapeutics) Wednesday July 6th 2016


24) Genome and Immune Profiling of Inflammatory Breast Cancer (Molecular Cancer Therapeutics) Wednesday July 6th 2016


25) Clinical Significance of TLR1 Polymorphism in mCRC (Molecular Cancer Therapeutics) Wednesday July 6th 2016


26) ATF3: A Biomarker for HDACi Treatment in Bladder Cancer (Molecular Cancer Therapeutics) Wednesday July 6th 2016


27) Role of PKC{delta} in Paclitaxel-Induced Apoptosis (Molecular Cancer Therapeutics) Wednesday July 6th 2016


28) Molecular Analysis of Androgen Receptor Mutants (Molecular Cancer Therapeutics) Wednesday July 6th 2016


29) Cyclin-Dependent Kinase 11 and Ovarian Cancer (Molecular Cancer Therapeutics) Wednesday July 6th 2016


30) Cell-Cycle Gene Aberrations in Cancer (Molecular Cancer Therapeutics) Wednesday July 6th 2016


31) PAXIP1 Potentiates WEE1 Inhibitor Action (Molecular Cancer Therapeutics) Wednesday July 6th 2016


32) MSK1 as a Candidate Gene for PI3K/mTOR Resistance (Molecular Cancer Therapeutics) Wednesday July 6th 2016


33) Low MSLN Shedding Enhances Efficacy of Anticancer Agents (Molecular Cancer Therapeutics) Wednesday July 6th 2016


34) PIM Inhibitors Selectively Kill Hypoxic Tumor Cells (Molecular Cancer Therapeutics) Wednesday July 6th 2016


35) Acquired Resistance to GSK2118436 in V600E-Mutant NSCLC (Molecular Cancer Therapeutics) Wednesday July 6th 2016


36) Multitarget mAb Mixture Overcomes Cetuximab Resistance (Molecular Cancer Therapeutics) Wednesday July 6th 2016


37) Antagonists of the IGF-I:IGFBP-3:VN Complexes (Molecular Cancer Therapeutics) Wednesday July 6th 2016


38) NK-92MI-FETZ-Based Cancer Therapy (Molecular Cancer Therapeutics) Wednesday July 6th 2016


39) LGR5-Targeted ADC Eradicates Gastrointestinal Tumors (Molecular Cancer Therapeutics) Wednesday July 6th 2016


40) AMG 337 Inhibits Growth of MET-Dependent Cancer Models (Molecular Cancer Therapeutics) Wednesday July 6th 2016


41) mTORC1/2 in Ovarian Cancer Platinum Resistance (Molecular Cancer Therapeutics) Wednesday July 6th 2016


42) Sensitizing TNBC to PI3K Inhibition by Cotargeting IGF1R (Molecular Cancer Therapeutics) Wednesday July 6th 2016


43) SRC Inhibition in Glioblastoma (Molecular Cancer Therapeutics) Wednesday July 6th 2016


44) Discovery of a Novel Tankyrase Inhibitor, K-756 (Molecular Cancer Therapeutics) Wednesday July 6th 2016


45) Src Inhibitor in Biliary Tract Cancer (Molecular Cancer Therapeutics) Wednesday July 6th 2016


46) I{kappa}B Kinase {beta} in Human Prostate Cancer (Molecular Cancer Therapeutics) Wednesday July 6th 2016


47) Triptolide Kills MDR Tumor Cells (Molecular Cancer Therapeutics) Wednesday July 6th 2016


48) Novel GSK3 Inhibitor for AML (Molecular Cancer Therapeutics) Wednesday July 6th 2016


49) Dasatinib/ARID1A Synthetic Lethality in OCCC (Molecular Cancer Therapeutics) Wednesday July 6th 2016


50) SAR260301 PI3K{beta}-Selective Inhibitor in PTEN-Mutated Melanoma (Molecular Cancer Therapeutics) Wednesday July 6th 2016


51) Synergistic Dual Drug Liposomes in Multiple Myeloma (Molecular Cancer Therapeutics) Wednesday July 6th 2016


52) Interfering lncRNA Consumes OncomiRs to Inhibit HCC (Molecular Cancer Therapeutics) Wednesday July 6th 2016


53) Plk1 Inhibitors in Cancer Therapy (Molecular Cancer Therapeutics) Wednesday July 6th 2016


54) Plasma Metabolome Changes in Response to PI3K Inhibition (Molecular Cancer Therapeutics) Thursday June 2nd 2016


55) TWIST1 Polymorphism Predicts Bevacizumab Efficacy (Molecular Cancer Therapeutics) Thursday June 2nd 2016


56) Rapid BRAF Mutation Testing in Cell-Free DNA (Molecular Cancer Therapeutics) Thursday June 2nd 2016


57) Targeting ANT2 in EGFR-TKI-Resistant NSCLC (Molecular Cancer Therapeutics) Thursday June 2nd 2016


58) TLR4 and Chemotherapy-Induced Toxicity (Molecular Cancer Therapeutics) Thursday June 2nd 2016


59) miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma (Molecular Cancer Therapeutics) Thursday June 2nd 2016


60) Edelfosine for Prostate Cancer (Molecular Cancer Therapeutics) Thursday June 2nd 2016


61) Dll4 Inhibition in Ovarian Cancer (Molecular Cancer Therapeutics) Thursday June 2nd 2016


62) Targeting Wee1 in a Proneural GBM Model (Molecular Cancer Therapeutics) Thursday June 2nd 2016


63) Trastuzumab Dysregulates HER2 and Inhibits Autophagy (Molecular Cancer Therapeutics) Thursday June 2nd 2016


64) Triglycyl Peptide Linker for ADCs (Molecular Cancer Therapeutics) Thursday June 2nd 2016


65) Therapeutic ADC Targeting SLITRK6 in Bladder Cancer (Molecular Cancer Therapeutics) Thursday June 2nd 2016


66) Knottin-Fc-Drug Con{#x0237}ugate as an Antitumor Agent (Molecular Cancer Therapeutics) Thursday June 2nd 2016


67) TRX-E-002-1 Prevents Ovarian Cancer Recurrence (Molecular Cancer Therapeutics) Thursday June 2nd 2016


68) DI-39 in GBM (Molecular Cancer Therapeutics) Thursday June 2nd 2016


69) Pituitary Tumor Treatment with PI3K/mTOR Inhibitors (Molecular Cancer Therapeutics) Thursday June 2nd 2016


70) PI3K/BMX Combination with BH3 Mimetic in SCLC (Molecular Cancer Therapeutics) Thursday June 2nd 2016


71) Pegfilgrastim and Anticancer Antibodies (Molecular Cancer Therapeutics) Thursday June 2nd 2016


72) Preclinical Evaluation of AMG 337 in HCC (Molecular Cancer Therapeutics) Thursday June 2nd 2016


73) Targeting the BET Family in Colorectal Cancer (Molecular Cancer Therapeutics) Thursday June 2nd 2016


74) Apratoxin A, a Novel Pancreas-Targeting Agent (Molecular Cancer Therapeutics) Thursday June 2nd 2016


75) Stem Cell-Based Gene Therapy for Bladder Cancer (Molecular Cancer Therapeutics) Thursday June 2nd 2016


76) CS-IVa-Be, a Novel IL6R Antagonist, Inhibits IL6/STAT3 (Molecular Cancer Therapeutics) Thursday June 2nd 2016


77) Targeting Hh Pathway by MK-4101 in Medulloblastoma and BCC (Molecular Cancer Therapeutics) Thursday June 2nd 2016


78) DETD-35 Overcomes Acquired Vemurafenib Resistance in Mice (Molecular Cancer Therapeutics) Thursday June 2nd 2016


79) Unbiased Oncology Combination Screen (Molecular Cancer Therapeutics) Thursday June 2nd 2016


80) Erlotinib Distribution in Pancreatic Cancer (Molecular Cancer Therapeutics) Thursday May 5th 2016


81) Predictive Biomarkers of Venetoclax Efficacy in Myeloma (Molecular Cancer Therapeutics) Thursday May 5th 2016


82) miR-532-5p Is an Ovarian Cancer Prognosis Marker (Molecular Cancer Therapeutics) Thursday May 5th 2016


83) Hyperpolarized 13C MRSI-Detectable Changes with GBM Treatment (Molecular Cancer Therapeutics) Thursday May 5th 2016


84) dPCR and RAS Pathway Genotyping for mCRC Anti-EGFR Therapy (Molecular Cancer Therapeutics) Thursday May 5th 2016


85) Vismodegib Reduces Mesothelioma Growth by Affecting Stroma (Molecular Cancer Therapeutics) Thursday May 5th 2016


86) PVT1 Promotes NSCLC Cell Proliferation by Regulating LATS2 (Molecular Cancer Therapeutics) Thursday May 5th 2016


87) Anti-CD20-Mediated Lymphoma Cell Senescence (Molecular Cancer Therapeutics) Thursday May 5th 2016


88) Effects of r-AtHSP70 on Breast Cancer Cells (Molecular Cancer Therapeutics) Thursday May 5th 2016


89) Protein Kinase Inhibitor H89 Enhances Immunotoxin Activity (Molecular Cancer Therapeutics) Thursday May 5th 2016


90) GRP78 Increases PDAC Chemoresistance (Molecular Cancer Therapeutics) Thursday May 5th 2016


91) BRD4 Regulates EZH2 Transcription in Bladder Cancer (Molecular Cancer Therapeutics) Thursday May 5th 2016


92) Antiangiogenic Activity of JQ1 (Molecular Cancer Therapeutics) Thursday May 5th 2016


93) STxB-Based Targeting of Gastric Cancer (Molecular Cancer Therapeutics) Thursday May 5th 2016


94) Polymer Therapeutics Overcome Chemotherapy Resistance (Molecular Cancer Therapeutics) Thursday May 5th 2016


95) CLPTM1L Antibodies for Pancreatic and Lung Cancer Therapy (Molecular Cancer Therapeutics) Thursday May 5th 2016


96) Immunokinase-Based B-Lymphotoxic Delivery of Activated DAPK1 (Molecular Cancer Therapeutics) Thursday May 5th 2016


97) Molecular Basis of VC-PABC Linker Instability (Molecular Cancer Therapeutics) Thursday May 5th 2016


98) FAP-Dependent DR5 Hyperclustering Drives Tumor Cell Death (Molecular Cancer Therapeutics) Thursday May 5th 2016


View: prev | next


Mitch Andre Garcia's Chem Feeds 2008-present

Some images have been reproduced by permission of The Royal Society of Chemistry. (RSC' RSS Policy)
Other images have been reproduced with permission of the American Chemical Society. (ACS' RSS Policy)
Few images have been reproduced with pending permission of Wiley-VCH. ()